| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| 10g | |||
| Other Sizes |
| Targets |
6-O-α-Maltosyl-β-cyclodextrin targets cholesterol molecules within cellular membranes. By forming soluble inclusion complexes with cholesterol, it effectively extracts cholesterol from cell membranes. This action modulates cellular cholesterol levels, which can influence membrane fluidity, signaling pathways, and lipid metabolism. The compound does not target a specific protein receptor but acts through direct physicochemical interaction with cholesterol.
|
|---|---|
| ln Vitro |
Cellular cholesterol is eliminated by Mal-β-CD from inclusion complexes, and cholesterol/Mal-β-CD inclusion complexes (CLM) can be added to compensate for Mal-β-CD-induced cellular cholesterol deficit without causing cytotoxicity [1].
In vitro, 6-O-α-Maltosyl-β-cyclodextrin demonstrates potent cholesterol-modifying activity. It can form soluble inclusion complexes with cholesterol. The compound is much less cytotoxic to human erythrocytes and Caco-2 cells compared to other cholesterol modifiers. This favorable toxicity profile makes it suitable for cell culture applications where cholesterol modulation is required. |
| ln Vivo |
In vivo, 6-O-α-Maltosyl-β-cyclodextrin has been used to modulate cholesterol levels in animal models. Its ability to extract cholesterol from tissues suggests potential applications in treating cholesterol-related disorders. However, detailed in vivo studies are limited. The compound's safety profile in animals appears favorable based on its low cytotoxicity in vitro.
|
| Enzyme Assay |
For in vitro binding assays, 6-O-α-Maltosyl-β-cyclodextrin can be evaluated for its ability to form inclusion complexes with cholesterol. The compound is incubated with cholesterol in aqueous solution, and complex formation is assessed by measuring cholesterol solubility or using techniques such as isothermal titration calorimetry or nuclear magnetic resonance spectroscopy. The binding affinity and stoichiometry can be determined from these experiments.
|
| Cell Assay |
For in vitro cell-based assays, 6-O-α-Maltosyl-β-cyclodextrin is typically tested on human erythrocytes or Caco-2 cells. Cells are treated with the compound at various concentrations (typically 0.1-10 mM) for 1-24 hours. Cholesterol extraction from cell membranes is measured using enzymatic cholesterol assays or by analyzing membrane cholesterol content. Cell viability is assessed using LDH release or MTT assays to evaluate cytotoxicity.
|
| Animal Protocol |
For in vivo animal experiments, 6-O-α-Maltosyl-β-cyclodextrin can be administered orally or intraperitoneally to rodents. Blood samples are collected to measure serum cholesterol levels. Tissue cholesterol content can be analyzed in liver, adipose tissue, and other organs. The compound's effect on cholesterol metabolism and its safety profile can be evaluated through histopathological examination of tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 6-O-α-Maltosyl-β-cyclodextrin are limited. As a large oligosaccharide with a molecular weight of 1459.27 g/mol and formula C₅₄H₉₀O₄₅, it is expected to have poor oral bioavailability due to its size and hydrophilicity. The compound is likely metabolized by gut microbiota or hydrolyzed by digestive enzymes. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for 6-O-α-Maltosyl-β-cyclodextrin indicate that it is much less cytotoxic to human erythrocytes and Caco-2 cells compared to other cholesterol modifiers. This suggests a favorable safety profile for in vitro applications. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human therapeutic use.
|
| References | |
| Additional Infomation |
6-O-α-Maltosyl-β-cyclodextrin is a research-use only compound and has not been approved for clinical applications. It is also known as 6-O-alpha-D-maltosyl-beta-cyclodextrin. Its molecular weight is 1459.27, and its formula is C₅₄H₉₀O₄₅. The compound is used as an additive to improve the solubility of drugs such as quetiapine. It is available from various research chemical suppliers for cholesterol metabolism research.
|
| Molecular Formula |
C54H90O45
|
|---|---|
| Molecular Weight |
1459.2654
|
| Exact Mass |
1458.475
|
| CAS # |
104723-60-6
|
| PubChem CID |
78357834
|
| Appearance |
White to off-white solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Index of Refraction |
1.719
|
| LogP |
-9.19
|
| Hydrogen Bond Donor Count |
27
|
| Hydrogen Bond Acceptor Count |
45
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
99
|
| Complexity |
2480
|
| Defined Atom Stereocenter Count |
44
|
| SMILES |
C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)OC[C@@H]3[C@@H]4[C@@H]([C@H]([C@H](O3)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](OC([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@@H]([C@@H]([C@H]9O)O)O[C@@H]1[C@H](O[C@H](O4)[C@@H]([C@H]1O)O)CO)CO)CO)CO)CO)CO)O)O)CO)O)O)O)O
|
| InChi Key |
QFSFPJHBIGWPMD-PBVGKYIBSA-N
|
| InChi Code |
InChI=1S/C54H90O45/c55-1-10-19(63)20(64)29(73)47(83-10)92-38-11(2-56)84-46(30(74)21(38)65)82-9-18-45-28(72)37(81)54(91-18)98-44-17(8-62)89-52(35(79)26(44)70)96-42-15(6-60)87-50(33(77)24(42)68)94-40-13(4-58)85-48(31(75)22(40)66)93-39-12(3-57)86-49(32(76)23(39)67)95-41-14(5-59)88-51(34(78)25(41)69)97-43-16(7-61)90-53(99-45)36(80)27(43)71/h10-81H,1-9H2/t10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20+,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46+,47-,48?,49-,50-,51-,52-,53-,54-/m1/s1
|
| Chemical Name |
(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-10-[[(2S,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-5,15,20,25,30,35-hexakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~68.53 mM)
H2O : ≥ 60.5 mg/mL (~41.46 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (1.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (68.53 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6853 mL | 3.4264 mL | 6.8527 mL | |
| 5 mM | 0.1371 mL | 0.6853 mL | 1.3705 mL | |
| 10 mM | 0.0685 mL | 0.3426 mL | 0.6853 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
